Should the concomitant use of erlotinib and acid-reducing agents be avoided? the drug interaction between erlotinib and acid-reducing agents

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 4, 2011, Pages 448-452

  Duong, Silvia ^a   Leung, Mova ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CREDIT VALLEY HOSPITAL   (Canada)

Author keywords

cimetidine; drug interaction; epidermal growth factor receptor inhibitor; Erlotinib; esomeprazole; famotidine; histamine 2 receptor antagonists; lansoprazole; nizatidine; omeprazole; pantoprazole; pH; proton pump inhibitors; rabeprazole; ranitidine; Tarceva

Indexed keywords

CIMETIDINE; ERLOTINIB; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG MIXTURE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; ANTACIDS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS; QUINAZOLINES;

EID: 82555192635     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210381794     Document Type: Review

References (30)

1. Gerber DE.. Targeted therapies. A new generation of cancer treatments. Am Fam Physician. 2008 ; 77: 311-319 (Pubitemid 351206593)
2. Hoffman-La Roche Limited. 'Product Monograph: Tarceva® Erlotinib Hydrochloride Tablets', Online Referencing, http://www.rochecanada.com/gear/ glossary/servlet/staticfilesServlet?type=data&communityId=re753001&id= static/attachedfile/re7300002/re77300002/AttachedFile-09855.pdf (accessed November 2009).
3. Siegel-Lakhai WS, Beijnen JH, Schellens JHM.. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and gefitinib (Iressa®). Oncologist. 2005 ; 10: 579-589 (Pubitemid 41429121)
4. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell-lung cancer. N Engl J Med. 2005 ; 353: 123-132 (Pubitemid 41058344)
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 ; 25: 1960-1966 (Pubitemid 46972777)
6. Genentech Inc. Prescribing Information: Tarceva(R), Online Referencing, http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf (accessed November 2009).
7. Canadian Institute for Health Information. 'Proton Pump Inhibitor Use in Seniors: An Analysis Focusing on Drug Claims 2001 to 2008', Online Referencing, http://www.cihi.ca/cihiweb/dispPage.jsp?cw-page=AR-3170-E (accessed February 2010).
8. AstraZeneca LP, U.S. Prescribing Information: Prilosec(R), Online Referencing. http://www1.astrazeneca-us.com/pi/Prilosec.pdf (accessed November 2009).
9. Miner P, Katz PO, Chen Y, Sostek M.. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003 ; 98: 2616-2620 (Pubitemid 38020098)
10. Castell D, Bagin R, Goldlust B, Major J, Hepburn B.. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005 ; 21: 1467-1474 (Pubitemid 40874164)
11. In: AHFS drug information 2008. Bethasda, MD: American Society of Health-System Pharmacists ; 2008: 3025-3032.
12. Konturek SJ, Obtulowicz W, Kwiecien N, Sito E, Mikos E, Oleksy J.. Comparison of ranitidine and cimetidine in the inhibition of histamine, sham-feeding, and meal-induced gastric secretion in duodenal ulcer patients. Gut. 1980 ; 21: 181-86 (Pubitemid 10082925)
13. Sewing KF, Billian A, Malchow H.. Comparative study with ranitidine and cimetidine on gastric secretion in normal volunteers. Gut. 1980 ; 21: 750-752 (Pubitemid 11209220)
14. Medsafe, New Zealand Medicines and Medical Devices Safety Authority. 'Tarceva® Data Sheet', Online Referencing, http://www.medsafe.govt.nz/profs/ Datasheet/t/tarcevatab.htm (accessed February 2010).
15. Van Erp NP, Gelderblom H, Guchelaar HJ.. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 ; 35: 692-706
16. Lachman L, Howden CW.. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol. 2000 ; 95: 57-61 (Pubitemid 30041535)
17. Moody DE. Part I: Central nervous system drugs-Drug interactions with benzodiazepines. Handbook of drug interactions: A clinical and forensic guide. 2003 ;: 39-41
18. Medscape. 'Antacid (Sodium Bicarbonate) Oral. Detailed Monograph', Online Referencing, http://www.medscape.com/druginfo/monograph?cid=med&drugid= 148158&drugname=Antacid+(Sodium+Bicarbonate)+Oral&monotype= monograph&monographid=382762&secid=6 (accessed February 2010).
19. Center for Biologics Evaluation and Research, US Food and Drug Administration. 'Guidance for Industry. Drug Interaction Studies-Study design, Data Analysis and Implications for Dosing and Labeling', Online Referencing, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf (accessed February 2010).
20. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001 ; 19: 3267-3279 (Pubitemid 32591445)
21. Lu JF, Eppler SM, Wolf J, et al. Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer. Clin Pharmacol Ther. 2006 ; 80: 136-145 (Pubitemid 44160689)
22. Calvo E, Malik SN, Siu LL, et al. Assessment of erlotinib pharmacodynamics in tumors and skin or patients with head and neck cancer. Ann Oncol. 2007 ; 18: 761-767 (Pubitemid 46523282)
23. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL.. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004 ; 22: 77-85 (Pubitemid 41095117)
24. Thomas F, Rochaix P, White-Koning M, et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer. 2009 ; 45: 2316-2323
25. Hidalgo M, Bloedow D.. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin Oncol. 2003 ; 30 (3 suppl 7). 25-33 (Pubitemid 36828625)
26. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer. 2006 ; 7: 389-394 (Pubitemid 44043548)
27. Hughes AN, O'Brien MER, Petty J, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol. 2009 ; 27: 1220-1226
28. Waller LL, Miller AA, Petty WJ.. Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Lung Cancer. 2010 ; 67: 12-16
29. Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006 ; 12: 2166-2171
30. DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Micromedex Healthcare ;